Neurosurgery Flashcards
<p>What is the adult prevalence of intracranial aneurysms?</p>
<p>2%</p>
<p>What is the mortality rate of ruptured aneurysms?</p>
<p>30-40%</p>
<p>What percent of ruptured aneurysms develop hydrocephalus?</p>
<p>15-20%</p>
<p>What percent of ruptured aneurysms develop cardiac issues?</p>
<p>50%</p>
<p>Summarize the rupture risk for aneurysm size based on the International Study of Unruptured Intracranial aneurysms? What kind of study was it?</p>
<p>prospective cohort</p>
<p>What percent of bacterial endocarditis patients have mycotic aneurysms?</p>
<p>5-15%</p>
<p>What were the conclusions of the Internation Subarachnoid Aneurysm Trial (ISAT)?</p>
<p>Initially, large difference in mortality favoring coiling over clipping at 1 year. At 5-year follow-up, no difference in mortality between the two groups, though the incidence of rebleeding and aneurysm recurrence was higher in the coiling group</p>
<p>What were the conclusions of the Barrow Ruptured Aneurysm Trial?</p>
<p>initial results at 1 year favoring coiling with regard to poor outcome. At 3-year follow-up, no difference between groups. The rate of recurrence, rebleeding, and aneurysm obliteration were better in the clipping group</p>
<p>What are the general morbidity and mortality for coiling and clipping aneurysms?</p>
<p>mortality (1–2% for surgery/<br></br>coiling) and morbidity (4% coiling and 8% surgery)</p>
<p>What is the hemorrhage rate for AVMs?</p>
<p>2-4% per year,6–18% in first year following initial hemorrhage if not treated. Lifetime risk of hemorrhage is 17–90%.</p>
<p>What is the mortality of AVM hemorrhage?</p>
<p>mortality 10–30%, morbidity 10–30%.</p>
<p>What are dural AVFs?</p>
<p>Pathological shunts between meningeal or extracranial arteries and the dural venous sinus, dural veins, or cortical veins</p>
<p>What is the Borden classification for dAVFs?</p>
<p>Borden I: Generally benign (conversion rate to higher grade ~ 2%), but occasionally symptoms warrant treatment.</p>
<p><br></br>Borden II: Hemorrhage in 18%, annual hemorrhage rate of 6%.</p>
<p><br></br>Borden III: Present with hemorrhage in 34%, annual hemorrhage rate of 10% which increases to 21% with venous ectasia.</p>
<p>What endovascular treatment is preferred for dAVF?</p>
<p>transvenous coiling</p>
<p>Moyamoya in asian adults usually causes \_\_\_\_\_ while in children usually \_\_\_\_\_. In American adults, it usually presents as \_\_\_\_.</p>
<p>hemorrhage</p>
<p></p>
<p>ischemia</p>
<p></p>
<p>ischemia</p>
<p>What is the difference between moyamoya disease and syndrome?</p>
<p>disease: idiopathic</p>
<p></p>
<p>syndrome: secondary</p>
<p>What is the risk of hemorrhage in cav mals?</p>
<p>Risk of symptomatic hemorrhage 0.5–2% per year, may be higher in patients with previous hemorrhages (~5% per year), deep lesions (~10% per year), posterior fossa lesions, familial inheritance, and women (~4% per year)</p>
<p>What does the ICH score predict? What are those values?</p>
<p>mortality at 30 days</p>
<p></p>
<p>ICH score</p>
<p>0: 0%</p>
<p>1: 13%<br></br>2: 26%</p>
<p>3: 72%</p>
<p>4: 97%</p>
<p>5: 100%</p>
<p>6: 100%.</p>
<p>What were the conclusions fo the STICH I and II trials?</p>
<p>supratentorial ICH surgical evacuation only mild benefit in long term mortality</p>
<p>What were the conclusions of the MISTIE trial?</p>
<p>minimally invasive clot aspiration + tPA: 50% reduction in clot burden and at 6 and 12 months increase in number of patients in mRS 0–3 category versus mRS 4 and above</p>
<p>What were the results of the CLEAR trial?</p>
<p>clot lysis of IVH with tPA through external ventricular drain (EVD): mortality rate of 18% in treatment group vs 23% in placebo group, similar ventriculitis rates ~8–9%</p>
<p>Malignant cerebral edema presents in what percent of MCA infarcts?</p>
<p>10%</p>
<p>What is the prevalence of carotid stenosis in the population?</p>
<p>2.5% for age < 65, 35% for age > 75</p>
<p>What percent fo CCFs are from trauma?</p>
<p>70%</p>
<p>What are the types of CCFs?</p>
<p>direct (carotid artery)</p>
<p></p>
<p>indirect (adjacent branch)</p>
<p>What is the presentation for CCFs?</p>
<p>Direct: orbital/retro-orbital pain, chemosis, pulsatile proptosis, ocular/cranial bruit, visual deterioration, diplopia, and ophthalmoplegia.</p>
<p></p>
<p>Indirect: more insidious onset. Conjunctival injection is most prominent feature</p>
<p>What is the management of low flow CCFs?</p>
<p>can be watched until they spontaneously thrombose if visual acuity stable and intraocular pressure < 25 mm Hg. Can also perform daily manual compression of cervical ICA</p>
<p>What percent of subdural empyema have an associated cerebral abscess?</p>
<p>25%</p>
<p>Where is the pterion?</p>
Located at the junction of the frontal, parietal, temporal, and greater wing of sphenoid bones
It is located two fingerbreadths above the zygomatic arch and a thumb’s breadth behind the frontal process of the zygomatic bone
Where is the asterion? What does it signify?
located at the junction of the lambdoid, occipitomastoid, and parietomastoid sutures
lies on top of the lower half of the transverse/ sigmoid sinus junction
<p>What is the bregma?</p>
<p>located at the junction of the coronal and sagittal sutures</p>
What genetic mutations are characteristic for IDH mutant diffuse astrocytomas?
ATRX loss and p53 mutation
Pilocytic astrocytomas on MRI imaging generally are ________ but when in the optic nerve, are generally _____.
cystic with mural nodule
solid and enhancing
<p>What disease is associated with pilocytic astrocytoma?</p>
<p>NF-1</p>
<p>What is the 5 and 10 yr survival for PXAs?</p>
<p>80 and 70%</p>
<p>What is the most common location for oligodendrogliomas?</p>
<p>frontal lobe (50%)</p>
<p>Most GBMs that develop from other astrocytomas are \_\_\_\_\_.</p>
<p>IDH mutants</p>
<p>What is the Stupp protocol?</p>
<p>maximal safe resection followed by adjuvant chemotherapy/radiation</p>
<p></p>
<p>fractionated radiationof 2 Gy 5 days/week for six weeks total 60 Gy, plus daily temozolomide at 75 mg/m^2, 7 days a week for 60 days followed by six cycles of adjuvant temozolomide 150-200 mg/m^2 for 5 of 28 days</p>
<p>In the fourth ventricle, ependymomas usually arise from the \_\_\_\_\_.</p>
<p>floor</p>
<p>Spinal ependymomas are associated with a syrinx in what percent of cases?</p>
<p>90%</p>
<p>"Tiger stripes" in unilaterally in the cerebellum are pathognomonic for \_\_\_\_\_.</p>
<p>Lhermitte Duclos disease</p>
<p>What is the treatment for Lhermitte Duclos disease?</p>
<p>surgical resection is curative</p>
<p>What is the chance for seizure freedom after DNET resection?</p>
<p>80% at 5 years, 60% at 10 years</p>
<p>What's the difference between a gangliocytoma and ganglioglioma?</p>
<p>Gangloicytoma: WHO grade I growth of mature neurons</p>
<p></p>
<p>Ganglioglioma: WHO grade I and II mixed population of ganglion and glial cells</p>
<p>What is the semiology of hypothalamic hamartomas? What other symptoms can they classically present with?</p>
<p>gelastic seizures</p>
<p></p>
<p>precocious puberty</p>
<p>What is the overall 5 year survival rate for paragangliomas?</p>
<p>90%</p>
<p>What percent of pineoblastomas have CSF seeding?</p>
<p>50%</p>
<p>What is the treatment for pineoblastoma?</p>
<p>surgical resection + cranial/spinal radiation and chemotherapy</p>
<p>What is the survival rate in pineoblastoma?</p>
<p>Fifteen percent 10-year survival in case of residual tumor versus 100% if no residual left</p>
<p>What chromosome abnormality can be seen with medulloblastoma?</p>
<p>loss of 17p in 50% of patients</p>